Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.51 |
| ▸ | CCR8 | P51685 | 5/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622655 | 0.81 | CCR1 (0.51) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL12932576 | 0.80 | CCR1 (0.58) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL15703117 | 0.74 | MEN1 (0.50) | CCR1CCR8NSD2CASP6CCR5 | |
| SCHEMBL242232 | 0.74 | SYK (0.51) | CCR1CCR8NSD2CASP6PDGFRB | |
| SCHEMBL243387 | 0.74 | KDM4E (0.45) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL14768504 | 0.73 | LMNA (0.59) | CCR1CCR8CCR5LMNACYP1A2 | |
| SCHEMBL6609520 | 0.73 | KDM4E (0.45) | CYP1A2KDM4EHPGDMAPTNPSR1 | |
| SCHEMBL3977326 | 0.72 | LMNA (0.63) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL4539236 | 0.71 | LMNA (0.52) | CCR1CCR8CCR5LMNACYP1A2 | |
| SCHEMBL29828916 | 0.71 | CYP1A2 (0.52) | CCR1CCR8LMNACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2349273-B1 | MODULATORS OF CXCR7 | CHEMOCENTRYX INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2349273-B1 | MODULATORS OF CXCR7 | CHEMOCENTRYX INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8853202-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054006-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014121-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | CCR1 19/4885CCR8 16/4885NSD2 2999/4885 |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | CCR1 19/4885CCR8 16/4885NSD2 2999/4885 |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | CCR1 19/4885CCR8 16/4885NSD2 2999/4885 |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | CCR1 1019/4885CCR8 1874/4885NSD2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.